Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 4,672 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Rhinitis, Allergic, Perennial
Interventions: fluticasone furoate nasal spray, vehicle placebo nasal spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 56
States / cities: Oxford, Alabama • Little Rock, Arkansas • Fresno, California + 49 more

Conditions: COVID-19, Oscillation and Lung Expansion
Interventions: MetaNeb® System; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia • Evanston, Illinois

Conditions: Bronchiolitis
Interventions: Standard Non-Invasive Mechanical Servo Ventilation, Neurally-Adjusted Ventilatory Assistance (NAVA) Non-Invasive Mechanical Servo Ventilation; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 0 Years to 2 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: counseling intervention, questionnaire administration, quality-of-life assessment; Other · Procedure
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: COVID-19, Pneumonia
Interventions: Heparin; Drug
Lead sponsor: University of Manitoba; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 13
States / cities: Atlanta, Georgia • Chicago, Illinois • Jefferson, Louisiana + 10 more

Conditions: Lung Cancer
Interventions: BBR 3464; Drug
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 18
States / cities: Hoover, Alabama • Fayetteville, Arkansas • Berkeley, California + 15 more

Conditions: Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Interventions: YL201, Atezolizumab; Drug
Lead sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Plantation, Florida • Louisville, Kentucky + 2 more

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions: Audiometric Test, Interview; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 51
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more

Conditions: Cystic Fibrosis
Interventions: Losartan, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Lorlatinib, Crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 34
States / cities: Altamonte Springs, Florida • Brandon, Florida • Clearwater, Florida + 23 more

Conditions: Asthma, Allergies
Interventions: Not listed
Lead sponsor: Ovation Research Group; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,500 participants
Timeline: Started 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Standard Coaching (SOC), MonitAir RPM; Behavioral
Lead sponsor: MonitAir; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions: NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Pulmonary Embolism
Interventions: SR34006, (LMW)heparin, Warfarin VKA, Acenocoumarol VKA; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 54
States / cities: Loma Linda, California • San Diego, California • Aurora, Colorado + 43 more

Conditions: Pneumonia, Blood Stream Infection
Interventions: colistin and meropenem, colistin and placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 95 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 6
States / cities: Miami, Florida • Detroit, Michigan • Royal Oak, Michigan + 2 more

Conditions: Hypoxic-ischemic Encephalopathy
Interventions: Dexmedetomidine; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Hour to 1 Day
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Delirium, Respiratory Depression, Overmedication
Interventions: Verum Acupuncture, Sham Acupuncture; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Dysphonia, Unilateral Vocal Cord Paralysis
Interventions: Standard of care voice therapy, Expiratory muscle strength training (EMST); Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: WIN378, Placebo; Drug
Lead sponsor: Windward Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Los Angeles, California • San Jose, California • Melbourne, Florida + 18 more

Conditions: Lung Cancer
Interventions: hematoporphyrin derivative, brachytherapy; Drug · Radiation
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions: Beta-lactam antibiotic, Aminoglycoside; Drug
Lead sponsor: Chris Goss; Other
Eligibility: 6 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 59
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 49 more

Conditions: Cystic Fibrosis
Interventions: LAU-7b, Placebo oral capsule; Drug
Lead sponsor: Laurent Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 27
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 24 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: San Diego, California • Torrance, California • Hartford, Connecticut

Search by objective public record fields.

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Oscillation and Lung Expansion Therapy in Patients With COVID-19

Non-Invasive Ventilation Versus Neurally-Adjusted Ventilatory Assistance (NAVA) for the Treatment of Bronchiolitis

Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Impact of Asthma Treatments on Daily Activities

MonitAir Remote Patient Monitoring Versus Standard of Care for CPAP Adherence in Obstructive Sleep Apnea

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)

Dexmedetomidine Pharmacokinetics in Neonates During Therapeutic Hypothermia

Acupuncture for Sedation in the Intensive Care Unit (ICU)

The Effects of Adding Expiratory Muscle Strength Training in Voice Therapy

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways